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Abstract
We investigated whether stratifying by the interval between first-line (T1) and second-line (T2) 
treatments could identify a subgroup of older patients with relapsed CLL/SLL with an expectation 
of normal overall survival. Longer time-to-T2 was associated with a modestly improved prognosis; 
however, even among those retreated ≥ 3 years after T1, survival was poor compared with the 
general population (5-year relative survival = 50%).
Background—Novel targeted therapies offer excellent short-term outcomes in patients with 
chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). However, there is 
disagreement over how widely these therapies should be used in place of standard chemo-
immunotherapy (CIT). We investigated whether stratification on the length of the interval between 
first-line (T1) and second-line (T2) treatments could identify a subgroup of older patients with 
relapsed CLL/SLL with an expectation of normal overall survival, and for whom CIT could be an 
acceptable treatment choice.
Patients and Methods—Patients with relapsed CLL/SLL who received T2 were identified 
from the SEER-Medicare Linked Database. Five-year relative survival (RS5; ie, the ratio of 
observed survival to expected survival based on population life tables) was assessed after 
stratifying patients on the interval between T1 and T2. We then validated our findings in the Mayo 
Clinic CLL Database.
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Results—Among 1974 SEER-Medicare patients (median age = 77 years) who received T2 for 
relapsed CLL/SLL, longer time-to-retreatment was associated with a modestly improved prognosis 
(P = .01). However, even among those retreated ≥ 3 years after T1, survival was poor compared 
with the general population (RS5 = 0.50 or lower in SEER-Medicare). Similar patterns were 
observed in the younger Mayo validation cohort, although prognosis was better overall among the 
Mayo patients, and patients with favorable fluorescence in situ hybridization retreated ≥ 3 years 
after T1 had close to normal expected survival (RS5 = 0.87).
Conclusion—Further research is needed to quantify the degree to which targeted therapies 
provide meaningful improvements over CIT in long-term outcomes for older patients with 
relapsed CLL/SLL.
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Introduction
Novel therapies available targeting Bruton’s tyrosine kinase, PI-3 kinase, and bcl-2 have 
demonstrated excellent short-term outcomes in patients with chronic lymphocytic leukemia 
and small lymphocytic lymphoma (CLL/SLL).1–3 Particularly for patients with an otherwise 
poor prognosis, these treatments are likely to be transformative. However, these agents must 
be taken indefinitely, are costly ($100,000–$150,000 annually),4,5 and carry risks of 
significant side effects (eg, atrial fibrillation, colitis, infection, and tumor lysis syndrome).6 
For these reasons, it is important to identify the CLL/SLL patients for whom these new 
agents are most likely to provide a meaningful benefit compared with standard chemo-
immunotherapy (CIT) regimens. Additionally, it would be useful to identify subgroups of 
patients with relapsed or refractory CLL/SLL who are at low risk for premature mortality 
with standard CIT options, and thus would have a suitable alternative to long-term use of 
newer agents.
In patients with relapsed CLL/SLL, the time interval from initial therapy until relapse is 
recognized as an important prognostic marker. Patients who relapse sooner are less 
responsive to subsequent treatments and have shorter overall survival (OS).7–9 This 
association has been characterized in a younger patient cohort (median age < 60 years) that 
received first-line treatment with fludarabine, cyclophosphamide, and rituximab (FCR). 
Median OS following relapse was 13 months among patients who relapsed in less than 3 
years, as compared with 63 months in those who relapsed in ≥ 3 years.10 However, because 
the median age at diagnosis for CLL/SLL is 71 years,11 these results may not be 
generalizable to most patients with CLL/SLL. Older patients typically receive less intensive 
antineoplastic therapies, and OS patterns following relapse are likely to be different in older 
adults due to competing risks of mortality. A more precise characterization of this 
relationship in older adults will inform clinicians’ efforts to risk-stratify and appropriately 
treat older patients with relapsed CLL/SLL.
In this study we assessed the prognostic value of time-until-retreatment in predicting 
subsequent OS among older CLL/SLL cases identified from the Surveillance, Epidemiology, 
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and End Results (SEER)-Medicare Linked Database (SEER-Medicare) and an independent 
validation cohort identified from the Mayo Clinic CLL Database. We hypothesized that, 
before the era of novel targeted therapies, patients retreated ≥ 3 years after their first course 
of antineoplastic therapy would have OS close to that expected in the US general population 
after controlling for age, sex, and calendar year.
Methods
Data Sources
The study data for the SEER-Medicare patient cohort were obtained from the 2014 SEER-
Medicare linkage, which included SEER cancer cases diagnosed from 1973 to 2011 and 
their Medicare claims from 1992 to 2013. Within SEER registry catchment areas, 93% of 
patients aged 65+ years diagnosed with cancer have been linked to their Medicare claims 
data.12 Participating registries collect data for all patients with cancer diagnosed within their 
defined geographic area. Registry data include month and year of diagnosis, age at 
diagnosis, race, tumor stage, and histology. Medicare files from the Centers for Medicare 
and Medicaid Services (CMS) include demographic and enrollment information, date of 
death, and all bills submitted for inpatient hospital care, outpatient hospital care, physician 
services, and prescription fills.
Normative mortality rates based on the US general population were obtained from The 
Human Mortality Database,13 which assembles historical US life tables based on data 
published by the US Census Bureau14 and National Center for Health Statistics.15 As 
described in the statistical methods section, these data were used for the relative survival 
estimates used to describe CLL/SLL patients’ prognosis compared with age- and sex-
matched controls.
Institutional Review Board Review and Research Ethics
This research project was approved by SEER-Medicare Program staff and the University of 
Iowa Institutional Review Board (IRB). The University of Iowa IRB granted a waiver of 
informed consent because the project consisted of a secondary analysis of existing data. 
SEER-Medicare Program staff reviewed the manuscript to ensure that it met reporting 
requirements to protect patient confidentiality. The validation study in the Mayo Clinic CLL 
Database, described at the end of the methods section, was performed with the approval of 
the Mayo Clinic IRB.
Cohort Definition
Our study population consisted of patients who at age ≥ 66 years were diagnosed with 
CLL/SLL from 1992 to 2011. Cases were excluded if they had no specific diagnosis month 
recorded by SEER, had a prior malignancy, had inconsistent birth or death dates recorded by 
SEER and CMS, were diagnosed at death, did not have microscopic or laboratory diagnostic 
confirmation, were not enrolled in traditional fee-for-service Medicare Parts A and B at 
diagnosis and the prior 365 days, or had claims for antineoplastic therapy before the 
diagnosis date recorded by SEER (Figure 1). The age and Medicare eligibility restrictions 
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ensured that we could evaluate patients’ receipt of antineoplastic therapy, comorbidity 
burden, and proxies for CLL/SLL progression using Medicare claims data.
Patients in this CLL/SLL inception cohort became eligible for inclusion in the present study 
on receiving first- and second-line courses of antineoplastic therapy. Follow-up began on the 
date that second-line therapy was initiated. Patients were excluded if prior to second-line 
treatment any of the following censoring events occurred: death, the end of the study period 
(December 31, 2013), loss of traditional Medicare enrollment, diagnosis with a second 
primary malignancy, or initiation of ibrutinib (a novel Bruton tyrosine kinase inhibitor 
initially approved in 2013). Cohort identification steps are shown in Figure 1.
We restricted our study sample to patients whose first course of antineoplastic therapy was 
no more than 365 days. For most CLL/ SLL chemotherapy regimens, the treatment plan 
would consist of 6 cycles of treatment at 4-week intervals. Some patients may discontinue 
treatment early or take breaks between treatment cycles, and treatment with some agents (eg, 
chlorambucil or rituximab monotherapy) may continue for 12 months. We further restricted 
to patients in whom the start of the second treatment course was at least 183 days after the 
end of the first treatment course. This requirement was motivated by concerns that parsing 
shorter gaps between treatment episodes into distinct treatment courses would be difficult 
based solely on claims data. In addition, patients who relapse fewer than 6 months after their 
last antineoplastic treatment are considered to have refractory CLL/SLL, and are known to 
have a poor prognosis.9,16
Exposure Definition
The main prognostic factor of interest was time-until-retreatment, defined as the difference 
in years between the end of the first course of antineoplastic therapy and the beginning of 
the second course of antineoplastic therapy. Receipt of antineoplastic treatment was assessed 
using procedure, diagnosis, and drug codes recorded in Medicare inpatient, outpatient, and 
prescription claims. See Supplemental Tables 1 and 2 (in the online version) for details on 
the codes and code ranges that were used. Corticosteroids were not included in our study 
definition of antineoplastic therapy because they are frequently used for other indications, 
and rarely used as monotherapy for CLL/SLL. Drug-specific Healthcare Common Procedure 
Coding System (HCPCS) and National Drug Codes (NDCs) were used to identify specific 
antineoplastic agents administered. Patients were classified as having received chemo-
immunotherapy (CIT), chemotherapy, or immunotherapy. More details on the specific 
treatment regimens that patients received are provided in Supplemental Table 3 (in the 
online version).
A course of treatment was defined as beginning on the start date associated with the first 
claim where antineoplastic therapy was recorded, continuing for as long as additional claims 
were observed (allowing for gaps of no more than 90 days), and ending on the end date of 
the last claim in the series. A prior chart validation study performed in patients with 
lymphoma found that Medicare claims data generally provide reliable information on 
whether and when patients receive chemotherapy.17
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Study Endpoint
The study endpoint was all-cause mortality. The SEER-Medicare dataset includes each 
patient’s date of death as recorded in the Social Security Death Master File. In the files used 
in the present study from the 2014 SEER-Medicare linkage, mortality data were available 
through the end of 2013. Patients who were alive on December 31, 2013, were right-
censored in our survival analyses.
Statistical Methods
Five-year relative survival (RS5) was used to characterize the prognosis of patients with 
CLL/SLL. RS5, the ratio of 5-year observed OS relative to OS in the general population 
after conditioning on age, sex, and calendar year, was estimated with the Ederer II 
method.18–20 RS measures are frequently used in cancer epidemiology as indirect estimates 
of the burden of cancer-specific mortality in defined patient populations. The statistical 
significance of differences and trends in RS across patient subgroups was assessed using the 
additive hazards model endorsed by Dickman et al19 for analyses of relative survival data 
within a generalized linear models framework.
Covariates
A number of demographic and clinical characteristics were assessed to characterize our 
study sample (see Table 1), and to explore possible modification of the relationship between 
time-to-retreatment and relative survival. As a summary measure of comorbidity burden, we 
report a count of the following 12 major comorbidities included in the National Cancer 
Institute and Charlson comorbidity indices21–23: cerebrovascular disease, chronic pulmonary 
disease, congestive heart failure, dementia, diabetes, hemiplegia/paraplegia, liver disease, 
myocardial infarction, peptic ulcer disease, renal disease, rheumatic disease, and human 
immunodeficiency virus infection. In addition, we provide data on the frequency of several 
health conditions associated with advanced CLL/SLL disease (eg, anemia and infection).
Health conditions and health care utilization were assessed based on administrative 
diagnosis codes recorded during the year before retreatment. Following the approach of 
Klabunde et al,23 a condition was considered present if a corresponding inpatient diagnosis 
code or 2 outpatient diagnosis codes 30+ days apart were observed. A higher standard was 
required for outpatient diagnosis codes, because they can sometimes reflect diagnoses that 
were ruled out or merely considered as part of a differential diagnosis.
Validation Study in Mayo Clinic CLL Database
Data for the validation cohort were obtained from the Mayo Clinic CLL Database with the 
approval of the Mayo Clinic IRB. The database includes patients with a diagnosis of 
CLL/SLL seen in the Division of Hematology at the Mayo Clinic since 1995. Clinical 
information regarding date of diagnosis, baseline evaluation, prognostic parameters, 
treatment history, and disease-related complications was abstracted from clinical records on 
all patients and maintained in the database on an ongoing prospective basis. Additional 
details about the Mayo Clinic CLL Database may be found in prior publications.24,25
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The validation study cohort included patients diagnosed with CLL/SLL from 1995 to 2013, 
and longitudinal follow-up data through 2016. All patients with CLL/SLL who received 
second-line therapy during this period were identified, classified based on the time-to-
retreatment, and followed until death or censoring. RS5 from the initiation of second-line 
therapy was estimated with the relsurv package for R.26,27 RS5 was estimated for patient 
subgroups defined by time-to-retreatment, type of first-line antineoplastic therapy received 
(CIT, chemotherapy, or immunotherapy), IGHV mutation status, and whether 11q or 17p 
chromosome deletions were detected through fluorescence in situ hybridization (FISH).
Results
During 1992 to 2011, there were 6044 CLL/SLL cases identified from SEER-Medicare who 
initiated first-line therapy and were eligible for continued follow-up. Of this group, 1974 
initiated second-line therapy before censoring and were included in our analyses (Figure 1). 
As first-line treatment, 693 patients had received CIT (35%), 824 chemotherapy alone 
(42%), and 457 immunotherapy alone (23%). Frequencies of specific treatment regimens are 
provided in Supplemental Table 3 (in the online version). At retreatment, the patients had a 
median age of 77 years (interquartile range: 73–82); 44% were women. Additional patient 
characteristics are shown in Table 1.
RS5 following second-line treatment was modestly higher in patients retreated ≥ 3 years 
after first-line treatment (0.49; 95% confidence interval, 0.40–0.58) compared with patients 
retreated in 6 months to < 2 years (0.42; 95% CI, 0.38–0.45) or 2 to < 3 years (0.42; 95% CI, 
0.35–0.50; test for trend: P = .01). The relationship between time-until-retreatment and 
subsequent RS5 varied by the type of first-line treatment received (Figure 2A). A protective 
association between longer time-until-retreatment and RS5 was seen among patients who 
received chemotherapy alone (P = .004) or CIT (P = .054). No clear pattern was observed in 
patients who received immunotherapy alone (P = .71) as first-line treatment.
In additional subgroup analyses, we explored whether the association between time-until-
retreatment and subsequent RS5 varied by number of treatment cycles received during first-
line therapy, patient age, or comorbidity burden. The relationship between longer time-until-
retreatment and improved subsequent RS5 was most pronounced among those whose first-
line treatment course included 3+ treatment cycles (Supplemental Figure 1 in the online 
version), who were 80+ years or older (Supplemental Figure 2 in the online version), and 
who had no major comorbidities (Supplemental Figure 3 in the online version). However, 
across all subgroups of retreated patients, survival was meaningfully reduced compared with 
appropriate age- and gender-matched cohorts from the US general population.
Mayo Clinic Validation Study
The validation cohort consisted of 508 patients identified from the Mayo Clinic CLL 
Database who received second-line antineo-plastic therapy. The median patient age was 66 
years (interquartile range: 59–74); 28% were women; and 58%, 29%, and 12% had received 
CIT, chemotherapy alone, and immunotherapy alone as first-line treatment, respectively (see 
Table 2). RS5 estimates were 0.52, 0.60, and 0.70 for patients retreated in 6 months to < 2 
years, 2 to < 3 years, and 3+ years, respectively (test for trend: P = .09). Similar patterns 
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were observed when patients were stratified by type of first-line antineoplastic therapy 
received (Figure 2A). In subgroup analyses, we stratified patients by IGHV mutation and 
FISH status. Time-to-retreatment was more strongly predictive of survival in patients with 
favorable FISH status (ie, no 11q or 17p deletions; Figure 3A) and in patients with 
unmutated IGHV (Figure 3B), although these trends did not reach statistical significance.
Discussion
In our primary population-based SEER-Medicare study of mortality among older patients 
with relapsed CLL/SLL who received second-line therapy, we found that longer time-until-
retreatment was associated with moderately improved subsequent RS5. Contrary to our 
initial study hypothesis, and in contradistinction to previous findings in follicular lymphoma 
(FL), another chronic B-cell malignancy, stratification on time-to-retreatment did not allow 
us to identify a patient subgroup with normal longevity. Even among patients retreated 3+ 
years after the end of first-line therapy, mortality was high among the SEER-Medicare 
patients relative to the general population (RS5 = 0.50). These results indicate that a 
significant number of older patients with relapsed CLL/SLL retreated with rituximabera CIT 
regimens are likely to have an unmet therapeutic need.
Overall, similar patterns were observed among patients in the Mayo Clinic CLL Database. 
Prognosis was better across the board for retreated patients in the younger Mayo cohort, 
with RS5 estimates ranging from 0.52 for patients retreated in 6 months to < 2 years to 0.70 
for patients retreated in 3+ years. It is possible that the better prognosis observed in the 
Mayo cohort relative to the SEER-Medicare cohort is attributable to its younger age (median 
age of 66 years vs. 77 years in SEER-Medicare cohort) and other case-mix differences, as 
well as differences in the selection of patients for treatment.
Because clinical prognostic markers were available in the Mayo Clinic CLL Database, we 
were able to stratify the Mayo cohort by IGHV and FISH status. These subgroup analyses 
suggested that time-to-retreatment had greater prognostic value among patients with 
unmutated IGHV and favorable FISH. Notably, among patients with time-to-retreatment ≥ 3 
years and favorable FISH, subsequent survival was close to normal (RS5 = 0.86). Survival 
was also close to normal for patients with time-to-retreatment ≥ 3 years who had received 
immunotherapy as first-line treatment (RS5 = 0.90).
Our results differ from those reported in prior work in FL, another typically chronic and 
indolent lymphoproliferative disease. In FL, it was demonstrated that early events following 
initial therapy are strongly predictive of subsequent outcomes, independent of baseline 
clinical prognostic scores.28 In patients with FL who received CIT as first-line treatment, 
disease progression within 24 months is predictive of meaningfully reduced OS. However, in 
patients with FL without an event in the 24 months following CIT (or 12 months following 
less aggressive treatment), OS is comparable to expected rates based on the age- and sex-
matched general population. Our differing results may be explained by differences in the 
biology of FL and CLL/SLL, and in the typical trajectory of disease progression following 
first-line treatment. In addition, the research questions in the FL study and ours were slightly 
different: we focused on survival outcomes among patients who initiated second-line 
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treatment, whereas the FL study sought to characterize subsequent survival trajectories 
among patients who at 24 months had not been retreated or experienced a relapse.
Our primary study relied on data available from SEER registries and Medicare claims, and 
thus had several limitations. Treatment dates and the type of antineoplastic therapy received 
were determined from procedure and diagnosis codes recorded by health care providers for 
reimbursement and Part D pharmacy claims. A prior validation study of billing codes for 
antineoplastic treatment in Medicare beneficiaries with lymphoma indicated that claims data 
generally provide valid information on chemotherapeutic agents and services dates.17 We 
would expect that modest misclassification of the timing and type of treatment would mean 
that the observed differences in RS5 across patient subgroups may underestimate the true 
between-group differences in survival outcomes. In addition, clinical prognostic markers 
were unavailable for the SEER-Medicare cohort.
Because our RS5 estimates reflect comparisons between observed and expected survival 
based on mortality rates observed in the US general population, it is important to consider 
the possibility of treatment selection bias. The patients in our SEER-Medicare and Mayo 
cohorts were all determined to be fit enough for first- and second-line antineoplastic therapy. 
For these reasons, our sample is likely to be slightly healthier than the general population in 
terms of comorbidity burden and functional status. Despite this possible source of bias 
toward improved survival outcomes in the patients with CLL/SLL who received 
antineoplastic therapy, survival rates were still meaningfully reduced among most patients 
receiving second-line therapy.
Our findings have several implications. During the rituximab era, most older patients with 
relapsed and retreated CLL/SLL had meaningfully reduced survival and a clear unmet 
therapeutic need. Possible exceptions, based on subgroup analyses in the younger Mayo 
cohort, were patients with favorable FISH and time-to-retreatment ≥ 3 years, or 
immunotherapy as first-line treatment and time-to-retreatment ≥ 3 years. Further research is 
needed to quantify the degree to which targeted therapies provide meaningful improvements 
over CIT in long-term outcomes for older patients with relapsed CLL/SLL.
Clinical Practice Point
• There is disagreement over how widely novel targeted therapies should be used 
in place of standard chemo-immunotherapy (CIT) for the treatment of CLL/SLL.
• We investigated whether stratifying by the interval between first-line (T1) and 
second-line (T2) treatments could identify a subgroup of older patients with 
relapsed CLL/SLL with an expectation of normal overall survival.
• Longer time-to-T2 was associated with a modestly improved prognosis; however, 
during the rituximab era, most older patients with relapsed and retreated 
CLL/SLL had meaningfully reduced survival and a clear unmet therapeutic need.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Flow Diagram Showing Identification of Eligible Surveillance, Epidemiology, and End 
Results (SEER)-Medicare Patients With Chronic Lymphocytic Leukemia or Small 
Lymphocytic Lymphoma (CLL/SLL)
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Figure 2. 
Estimated 5-year Relative Survival Following Initiation of Second-Line Treatment in the 
Surveillance, Epidemiology, and End Results (SEER)-Medicare Chronic Lymphocytic 
Leukemia/Small Lymphocytic Lymphoma Patient Cohort (A) and Mayo Validation Cohort 
(B)
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Figure 3. 
Estimated 5-year Relative Survival Following Initiation of Second-Line Treatment in the 
Mayo Validation Cohort, Stratified by Fluorescence In Situ Hybridization and IGHV 
Mutation Status
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Table 1
Characteristics of Eligible Patients Who Received Second-Line Treatment Stratified by First-Line Therapy
Characteristic
All Treatments (n 
= 1974)
Chemo-
immuno-
therapy (n = 
693)
Chemotherapy 
Alone (n = 824)
Immunotherapy 
Alone (n = 457)
Age at second-line treatment in years
 66–74 653 (33) 277 (40) 268 (33) 108 (24)
 75–79 577 (29) 202 (29) 261 (32) 114 (25)
 80+ 744 (38) 214 (31) 295 (36) 235 (51)
Sex
 Female 874 (44) 266 (38) 388 (47) 220 (48)
 Male 1100 (56) 427 (62) 436 (53) 237 (52)
Number of treatment cycles included in first-
line treatment course
 1–2 650 (33) 109 (16) 231 (28) 310 (68)
 3+ 1324 (67) 584 (84) 593 (72) 147 (32)
Interval between first- and second-line 
antineoplastic treatments
 6 mo to <2 y 1325 (67) 434 (63) 531 (64) 360 (79)
 2 y to <3 y 355 (18) 155 (22) 142 (17) 58 (13)
 3+ y 294 (15) 104 (15) 151 (18) 39 (9)
Type of second-line antineoplastic treatment
 Chemo-immunotherapy 576 (29) 298 (43) 183 (22) 95 (21)
 Chemotherapy alone 486 (25) 80 (12) 375 (46) 31 (7)
 Immunotherapy alone 609 (31) 207 (30) 122 (15) 280 (61)
 Unknown (nonspecific billing codes) 303 (15) 108 (16) 144 (17) 51 (11)
Indicators of CLL/SLL progression
 Anemia 916 (46) 331 (48) 345 (42) 240 (53)
 Thrombocytopenia 358 (18) 145 (21) 135 (16) 78 (17)
 Immune deficiency 282 (14) 147 (21) 93 (11) 42 (9)
Count of major comorbiditiesa
 None 964 (49) 330 (48) 420 (51) 214 (47)
 1 566 (29) 197 (28) 236 (29) 133 (29)
 2 or more 444 (22) 166 (24) 168 (20) 110 (24)
Hospitalized in prior year 777 (39) 269 (39) 335 (41) 173 (38)
Values are n (%).
Abbreviation: CLL/SLL = chronic lymphocytic leukemia or small lymphocytic lymphoma.
a
The major comorbidities covariate, adapted from the National Cancer Institute and Charlson comorbidity indices, is a count of the following 12 
comorbidities: cerebrovascular disease, chronic pulmonary disease, congestive heart failure, dementia, diabetes, hemiplegia/paraplegia, liver 
disease, myocardial infarction, peptic ulcer disease, renal disease, rheumatic disease, and human immunodeficiency virus infection.
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Table 2
Baseline Characteristics of Eligible Patients in Mayo Validation Cohort Who Received Second-Line Treatment
Characteristic Patient Count (n = 508), n (%)
Age at second-line treatment in years
 ≤65 245 (48)
 66–74 148 (29)
 75–79 77 (15)
 80+ 38 (7)
Sex
 Female 144 (28)
 Male 364 (72)
Type of first-line treatment received
 Chemo-immunotherapy (CIT) 295 (58)
 Chemotherapy alone 148 (29)
 Immunotherapy alone 59 (12)
Missing 6 (1)
Interval between end of first-line therapy and start of second-line therapy
 6 mo to <2 y 275 (54)
 2 y to <3 y 105 (21)
 3+ y 128 (25)
Fluorescence in situ hybridization status
 High risk (11q- or 17p-) 52 (10)
 Other/favorable 187 (37)
 Missing 269 (53)
IGHV mutation status
 Unmutated 217 (43)
 Mutated 84 (17)
 Missing 207 (41)
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